This is a key consideration for drugs/drug targets for Alzheimer’s disease prevention, since some clinical trials on targets with genetic evidence, such as β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors, failed to show efficacy after billions of US dollars of investments in pharma [46]. This evidence concerns the gene BACE1 and Alzheimer disease.